Braidwell LP Has $9.24 Million Stake in Sionna Therapeutics, Inc. $SION

Braidwell LP lowered its position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 71.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 314,013 shares of the company’s stock after selling 767,842 shares during the period. Braidwell LP owned about 0.70% of Sionna Therapeutics worth $9,235,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. bought a new position in Sionna Therapeutics in the first quarter valued at about $667,000. Woodline Partners LP bought a new stake in shares of Sionna Therapeutics during the first quarter worth about $837,000. Geode Capital Management LLC increased its stake in shares of Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after buying an additional 153,712 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Sionna Therapeutics in the second quarter valued at approximately $45,000. Finally, JPMorgan Chase & Co. raised its holdings in Sionna Therapeutics by 2.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock valued at $38,538,000 after buying an additional 51,589 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SION shares. Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Citigroup started coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set an “outperform” rating for the company. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Finally, Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.57.

Sionna Therapeutics Price Performance

Shares of SION stock opened at $37.32 on Friday. The business’s 50 day simple moving average is $38.53 and its 200 day simple moving average is $35.97. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00. The stock has a market capitalization of $1.68 billion and a PE ratio of -19.14.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15.

Insider Activity

In other news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the insider directly owned 6,494,962 shares in the company, valued at $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peter A. Thompson sold 29,063 shares of Sionna Therapeutics stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the transaction, the director directly owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. This represents a 0.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 382,368 shares of company stock valued at $15,898,607. 3.90% of the stock is currently owned by insiders.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.